Drug intelligence / Profile preview

Vismax

Development stage: Phase 4
Lead developer: Pharma Innova
Modality: Small Molecules
Administration: Ophthalmic

Overview

Vismax is a preservative-free ophthalmic solution containing 0.28% sodium hyaluronate, developed for the treatment of moderate to severe dry eye disease. Sodium hyaluronate is a high-molecular-weight polysaccharide that acts as a lubricant and viscoelastic agent, mimicking the properties of natural tears to improve ocular surface hydration and stability. By binding to water and adhering to the corneal epithelium, it increases tear film breakup time (TBUT) and reduces ocular surface damage. The Department of Medical Services of the Ministry of Public Health of Thailand has evaluated its efficacy and safety in comparison to other concentrations of sodium hyaluronate, such as 0.18% formulations.

Brand names: Vismax
Other names: 0.28% Sodium Hyaluronate0.28% preservative-free sodium hyaluronate

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Vismax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vismax.

Explore the full profile